| Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label … S Grosicki, M Simonova, I Spicka, L Pour, I Kriachok, M Gavriatopoulou, ... The Lancet 396 (10262), 1563-1573, 2020 | 274 | 2020 |
| Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk S Richard, A Chari, S Delimpasi, M Simonova, I Spicka, L Pour, I Kriachok, ... American Journal of Hematology 96 (9), 1120-1130, 2021 | 25 | 2021 |
| Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma HW Auner, M Gavriatopoulou, S Delimpasi, M Simonova, I Spicka, L Pour, ... American Journal of Hematology 96 (6), 708-718, 2021 | 21 | 2021 |
| Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma MV Mateos, M Gavriatopoulou, T Facon, HW Auner, X Leleu, R Hájek, ... Journal of Hematology & Oncology 14, 1-5, 2021 | 18 | 2021 |
| Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated … S Delimpasi, MV Mateos, HW Auner, M Gavriatopoulou, MA Dimopoulos, ... Am J Hematol 97 (3), E83-E6, 2022 | 11 | 2022 |
| Clinical outcomes in patients (Pts) with dose reduction of selinexor in combination with bortezomib, and dexamethasone (XVd) in previously treated multiple myeloma from the … S Jagannath, T Facon, AZ Badros, M Levy, P Moreau, S Delimpasi, ... Blood 138, 3793, 2021 | 11 | 2021 |
| Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone L Sanchez, X Leleu, JL Beaumont, H Yu, S Hudgens, M Simonova, ... American journal of hematology 96 (10), E383-E386, 2021 | 9 | 2021 |
| Hepatitis B in hepatocellular carcinoma patients and its correlation with alpha-fetoprotein and liver enzymes R Surit, R Shekhar, DK Sinha, SK Singh, U Kumar, N Prasad Journal of Cancer Research and Therapeutics 18 (4), 903-906, 2022 | 6 | 2022 |
| Once weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma: high-risk … S Richard, A Chari, S Delimpasi, M Simonova, I Spicka, L Pour, ... Blood 136, 35-36, 2020 | 6 | 2020 |
| Once weekly selinexor, bortezomib, and dexamethasone versus twice weekly bortezomib and dexamethasone in relapsed or refractory multiple myeloma: age and frailty subgroup … HW Auner, M Gavriatopoulou, S Delimpasi, M Simonova, I Spicka, L Pour, ... Blood 136, 17-18, 2020 | 4 | 2020 |
| Genomic pattern of GSTM1 and T1 gene null polymorphism of head and neck cancer patients in Eastern India R Surit, S Kumar, DK Sinha, R Shekhar Asian Pacific Journal of Cancer Prevention: APJCP 23 (8), 2655, 2022 | 3 | 2022 |
| Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study. T Facon, HW Auner, M Gavriatopoulou, S Delimpasi, M Simonova, ... Journal of Clinical Oncology 39 (15_suppl), 8019-8019, 2021 | 2 | 2021 |
| Impact of prior therapies on the safety and efficacy of once weekly selinexor, bortezomib, and dexamethasone compared with twice weekly bortezomib and dexamethasone in relapsed … M Mateos, S Jagannath, S Delimpasi, M Simonova, I Spicka, L Pour, ... Blood 136, 50-52, 2020 | 2 | 2020 |
| Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd) NJ Bahlis, S Richard, DJ White, S Grosicki, C Chen, S Delimpasi, ... Blood 138, 1634, 2021 | 1 | 2021 |
| Mucormycosis during COVID-19 era: Double whammy in the pandemic K Kishor, SS Pawar, M Kumar, S Raj, DK Sinha, D Kumar, A Kumar, ... Journal of Indira Gandhi Institute Of Medical Science 7 (2), 124-127, 2021 | 1 | 2021 |
| Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly … M Mateos, M Gavriatopoulou, T Facon, HW Auner, X Leleu, R Hajek, ... Blood 136, 48-50, 2020 | 1 | 2020 |
| Brain tumor management amidst COVID-19 pandemic K Kishor, DK Sinha, M Kumar, SS Pawar, R Madhawi, S Raj, RK Singh, ... Asian Pacific Journal of Cancer Care 5 (S1), 235-238, 2020 | 1 | 2020 |
| To Evaluate the Incidence of ER, PR and Her2/Neu Status in Newly Diagnosed Breast Cancer Patients at a Tertiary Care Centre DK Sinha, A Kumari, S Pankaj, S Kumari, V Choudhary, A Kumari, ... Indian Journal of Gynecologic Oncology 16, 1-5, 2018 | | 2018 |
| CARCINOMA OF RECTUM IN A 9 YEAR OLD GIRL A RARE CASE REPORT S Meedimale, RK Singh, S Devi, DK Sinha, R Madhawi Journal of Indira Gandhi Institute Of Medical Science 4 (1), 54-55, 2018 | | 2018 |
| A Study Of Districtwise Distribution Of Carcinoma Gall Bladder Cases Reporting To Regional Cancer Centre Of Bihar And Its Correlation With High Arsenic Zones Of The State. R Madhawi, DK Sinha, RK Singh Journal of Cancer Research & Therapeutics 13, 2017 | | 2017 |
